Unknown

Dataset Information

0

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.


ABSTRACT: The combination of viral vaccination with intratumoral (IT) administration of CpG ODNs is yet to be investigated as an immunotherapeutic treatment for solid tumors. Here, we show that such a treatment regime can benefit survival of tumor-challenged mice. C57BL/6 mice bearing ovalbumin (OVA)-expressing EG.7 thymoma tumors were therapeutically vaccinated with adenovirus type 5 encoding OVA (Ad5-OVA), and the tumors subsequently injected with the immunostimulatory TLR9 agonist, CpG-B ODN 1826 (CpG), 4, 7, 10, and 13 days later. This therapeutic combination resulted in enhanced mean survival times that were more than 3.5× longer than naïve mice, and greater than 40% of mice were cured and capable of resisting subsequent tumor challenge. This suggests that an adaptive immune response was generated. Both Ad5-OVA and Ad5-OVA + CpG IT treatments led to significantly increased levels of H-2 K(b)-OVA-specific CD8+ lymphocytes in the peripheral blood and intratumorally. Lymphocyte depletion studies performed in vivo implicated both NK cells and CD8+ lymphocytes as co-contributors to the therapeutic effect. Analysis of tumor infiltrating lymphocytes (TILs) on day 12 post-tumor challenge revealed that mice treated with Ad5-OVA + CpG IT possessed a significantly reduced percentage of regulatory T lymphocytes (Tregs) within the CD4+ lymphocyte population, compared with TILs isolated from mice treated with Ad5-OVA only. In addition, the proportion of CD8+ TILs that were OVA-specific was reproducibly higher in the mice treated with Ad5-OVA + CpG IT compared with other treatment groups. These findings highlight the therapeutic potential of combining intratumoral CpG and vaccination with virus encoding tumor antigen.

SUBMITTER: Geary SM 

PROVIDER: S-EPMC4358758 | biostudies-literature | 2011 Sep

REPOSITORIES: biostudies-literature

altmetric image

Publications

Tumor immunotherapy using adenovirus vaccines in combination with intratumoral doses of CpG ODN.

Geary S M SM   Lemke C D CD   Lubaroff D M DM   Salem A K AK  

Cancer immunology, immunotherapy : CII 20110528 9


The combination of viral vaccination with intratumoral (IT) administration of CpG ODNs is yet to be investigated as an immunotherapeutic treatment for solid tumors. Here, we show that such a treatment regime can benefit survival of tumor-challenged mice. C57BL/6 mice bearing ovalbumin (OVA)-expressing EG.7 thymoma tumors were therapeutically vaccinated with adenovirus type 5 encoding OVA (Ad5-OVA), and the tumors subsequently injected with the immunostimulatory TLR9 agonist, CpG-B ODN 1826 (CpG)  ...[more]

Similar Datasets

| S-EPMC5542240 | biostudies-literature
| S-EPMC7490994 | biostudies-literature
| S-EPMC10846067 | biostudies-literature
| S-EPMC7281656 | biostudies-literature
| S-EPMC3096725 | biostudies-literature
| S-EPMC7191058 | biostudies-literature
| S-EPMC4741610 | biostudies-literature
| S-EPMC5874308 | biostudies-literature
| S-EPMC6542562 | biostudies-literature
| S-EPMC8156017 | biostudies-literature